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Autologous hematopoietic stem cell transplantation (ASCT) is a curative option alternative to allogeneic
transplantation for patients with acute myeloid leukemia (AML). Relapse after ASCT can be due to contam-
ination with leukemic blasts of autologous peripheral blood stem cells (PBSCs) collected by leukapheresis
(LK). Identiﬁcation and quantiﬁcation of a minimal residual disease (MRD) marker in PBSCs could be relevant
in determining the relapse risk after ASCT. High levels of the WT1 gene transcript in bone marrow of AML
patients after treatment completion predict disease relapse. We evaluatedWT1 transcript levels in autologous
PBSC from LK used for ASCT in 30 consecutive AML patients in complete remission (CR) and established a
correlation with clinical outcome. At diagnosis, all patients had WT1 overexpression. All patients were in
morphological and genetic CR at the time of PBSC collection and before ASCT. Real-time quantitative PCR of
WT1 was performed in samples of each LK, using TaqMan technology on RNA from mononucleated cells. The
median WT1 transcript level in the PBSC graft (WT1-LK) of patients who relapsed was signiﬁcantly higher
than of those who did not relapse after transplantation (P <.0001). We deﬁned a cut-off level of 80 WT1-LK
copies/ABL 10e4 copies to discriminate between positive and negative PBSC grafts. The cut-off level was
strongly associated with disease recurrence, DFS and OS. Our study represents the largest series of patients
evaluating WT1 as a marker of MRD in PBSC LK products using a completely standardized real-time WT1-
reverse transcriptase-PCR based assay. These data, if conﬁrmed by prospective study, will help to determine
an individual patient’s adapted postremission allocation strategy.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Conventional treatment of acute myeloid leukemia (AML)
consists of remission induction and postremission or consol-
idation therapy. Induction results in complete remission (CR)
in 70% to 80% of younger and 50% to 60% of elderly patients.
Consolidation therapy after attaining remission is necessary to
prevent relapse. More than 50% of patients, however, experi-
ence disease recurrence during or after treatments.
Remission induction with a combination of cytarabine
and anthracycline is the current standard for patients eligible
for a curative approach. Postremission treatments includeedgments on page 1591.
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14.06.017chemotherapy with high-dose cytarabine, allogeneic he-
matopoietic stem cell transplantation, or autologous
hematopoietic stem cell transplantation (ASCT) [1]. The
choice of the best postremission strategy is usually based on
a risk-adapted approach together with evaluation of patient
comorbidities and donor availability.
Allogeneic hematopoietic stem cell transplantation after
an initial CR (CR1) is the best option for AML with interme-
diate or high genetic risk and/or other adverse prognostic
factors (eg, hyperleucocytosis, therapy related). ASCT is
considered for consolidation in low and intermediate cyto-
genetic groups and for high-risk patients with no allogeneic
transplant option available [2] because it offers an advantage
compared with chemotherapy [3], showing a lower relapse
incidence in newly diagnosed AML patients in CR1 [4].
The persistence of minimal residual disease (MRD) in the
bone marrow (BM) and/or the contamination with leukemicTransplantation.
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cells (PBSCs) collected by leukapheresis (LK) may limit the
potential beneﬁt of ASCT in AML. Identiﬁcation and quanti-
ﬁcation of a reliable marker of MRD in the BM and LK of
autologous PBSCs could be relevant in determining the
relapse risk after ASCT. Multiparameter ﬂow cytometry, PCR,
and ﬂuorescence in situ hybridization are useful tools for
detection of MRD in AML patients. PCR-based quantiﬁcation
of MRD has a higher sensitivity, but its applicability is
restricted to subgroups of AML with leukemia-speciﬁc
molecular targets (eg, AML1-ETO, CBFb-MYH11, NPM1).
These cases comprise less than 40% of all AML cases. The
Wilms’ tumor gene 1 is overexpressed in more than 90% of
AML patients at diagnosis. Several studies have shown that
quantiﬁcation ofWilms’ tumor gene 1 transcriptsWT1 in the
BM and PB of patients in CR after induction and consolidation
therapy demonstrated high prognostic value, irrespectively
of cytogenetic or molecular abnormalities, reliably discrim-
inating among patients at different risk of relapse [5].
Moreover, elevated levels of WT1 in BM harvest have been
associated with a higher relapse risk in patients autografted
for AML [6]. Siehl et al. [7] showed that PBSCs from AML
patients have signiﬁcantly higher WT1 levels as compared
with those obtained from solid cancer patients, indicating a
possible contamination with leukemic blasts.
In our study, we measured by European LeukemiaNet
(ELN) standardized assay [8] WT1 transcript levels in PBSCs
from LK (WT1-LK) used for ASCT in 30 consecutive AML
patients in CR1. We then established a correlation with
clinical outcome.METHODS
Patient Characteristics
Samples from LK products and from BM, at diagnosis and subsequent
controls; clinical data; and outcomes were available from 30 consecutive
patients with a diagnosis of AML who received an ASCT when in CR1 be-
tween August 2005 and February 2013. Eighteen patients were treated at
the Hematology and Bone Marrow Transplantation Unit of the San Raffaele
Scientiﬁc Institute and 12 patients at the Division of Hematology and Bone
Marrow Transplantation of the University of Udine.
According to the ELN genetic prognostic classiﬁcation of AML, 4 patients
(13%) were in the favorable group, 23 (77%) in intermediate-I, 0 in
intermediate-II, and 3 (10%) in the adverse group [1]. At diagnosis, all pa-
tients had WT1 overexpression.
All patients were in CR1 before PBSC collection, after 1 or 2 induction
cycles, and at least 1 consolidation cycle containing high-dose cytarabine.
Median patient age was 61 years (range, 28 to 76), and other patient and
disease characteristics are summarized in Table 1. Data were analyzed on
March 31, 2013.Treatment and WT1 Monitoring
Induction chemotherapy consisted of the combination of ﬂudarabine
(30 mg/m2 on days 1 to 5), cytarabine (2 g/m2 days 1 to 5), and idarubicin
(10 mg/m2 on days 1 to 3) (19 patients) or of daunorubicin (60 mg/m2 on
days 1 to 3) and continuous infusion cytarabine (100 mg/m2 on days 1 to 7)
(34 patients) or of idarubicin or daunorubicin associated with continuous
infusion of cytarabine and etoposide (100 mg/m2 on days 1 to 7) (idarubicin
regimen, 3 patients; daunorubicin regimen, 1 patient). Three patients
received 2 induction cycles.
After induction, all patients received 1 or 2 courses of consolidation
treatments containing high-dose cytarabine. PBSC LK was performed after
the last course. ASCT with myeloablative conditioning was administered as
ﬁnal consolidation. The following conditioning regimens were used:
busulfan 16 mg/kg þ cyclophosphamide 120 mg/kg for 13 patients and
treosulfan 30 g/m2 þ ﬂudarabine 150 mg/m2 þ cytarabine 10 g/m2 for 17
patients. PBSC graft was 4.94 106/kg CD34þ cells (range, 1.90 to 9.10  106/
kg). Treatments were administered according to the policy of each center.
All patients were in morphological and cytogenetic CR1 at the time of
PBSC collection and before ASCT. Deﬁnition of response to therapy was
expressed according to the published National Cancer Institute criteria,
revised by the International Working Group [9]. After ASCT, no furthertreatments were administered to patients in continuous CR, up to last
contact.
WT1 cut-off values for pathological samples were deﬁned as higher than
250 copies WT1/104 ABL copies in BM, according to Cilloni et al. [8]. WT1
levels were assessed at diagnosis, in the BM before LK, in the LK product, and
before ASCT. After ASCT,WT1 levels were assessed in BMmonthly during the
ﬁrst 3 months; at months 6, 9, and 12, and then annually or if clinically
relevant.PBSC Collection and Cryopreservation
PBSCs were collected using the COBE Spectra Apheresis System (Terumo
BCT, Inc., Lakewood, CO) by continuous collection with manual control of
hematocrit or automatic spill-over protocol. PBSCs were cryopreserved and
stored according to Jacie Standards, 2nd to 5th editions.SAMPLE PREPARATION AND QUANTIFICATION OF WT1
TRANSCRIPTS
The quantitative assessment of WT1 transcripts was per-
formed using real-time quantitative PCR (RQ-PCR) on mRNA
of mononuclear cells from LK samples, which had been
frozen immediately after collection and thawed immediately
before PCR analysis. Mononuclear cells were obtained by
Ficoll Hypaque density gradient centrifugation and stored at
80C. Total RNA was then extracted by phenol-chloroform
assay (TRIzol, Life Technologies, Grand Island, NY) and ret-
rotranscribed by the BIOMED 1 adapted protocol (standard-
ized RT-PCR protocol according to report of the BIOMED 1
[Biomedecine and Health Programme] concerned action and
modiﬁed according to EAC protocol [Europe Against Can-
cer]). Starting from 1 mg of total RNA, random hexamers were
used at a concentration of 50 mM, and 100 U of the reverse
transcriptase were added to the reaction mixture to obtain
signiﬁcant enhancement of the assay sensitivity. Finally, RQ-
PCR assays were performed on cDNA to amplify and simul-
taneously quantify WT1 transcripts [10,11].
WT1 transcripts were quantiﬁed using the TaqMan tech-
nology, through the WT1 ProﬁleQuant kit ELN (QIAGEN
Sciences, Germantown, MD), whose components have been
validated together in the context of a collaborative study led
by a group of experts from the ELN consortium. This kit in-
cludes plasmids speciﬁc for WT1 and ABL respectively, and
speciﬁc primers and FAM-TAMRA probe mixes for WT1 and
ABL.WT1 primers and probes were localized on exons 1 and
2. The WT1 ProﬁleQuant (ELN) assay uses validated standard
curves plasmid-based (3 plasmid standard dilutions for the
ABL control gene and 5 standard dilutions for theWT1 gene)
to calibrate and normalize the RQ-PCR results. By generating
standard curves based on the known concentration of
plasmid dilutions of both genes, it precisely measures the
copy number of the ABL control and WT1 transcript in hu-
man cell samples. The WT1 transcript values obtained were
normalized with respect to the number of ABL transcripts
and expressed asWT1 copy number every 10e4 copies of ABL
(WT1/ABL 10e4).Statistical Analysis
Clinical characteristics and response rates of the thera-
peutic subgroups were compared using the chi-square test or
Fisher exact test for categorical variables, according to the
sample size. To assess whether the population mean ranks
differ, the Wilcoxon signed-rank test was used (Mann-
Whitney U test). Survival curves were constructed according
to the method of Kaplan-Meier [12] and compared using the
log rank test. Differences were considered signiﬁcant when
P .05 (2-tailed). All survival analyses were performed using
the SPSS, version 14 (IBM Corporation, Armonk, NY).
Table 1
Patient Characteristics
Patient No. Age (yr) FAB Cytogenetic or
Molecular Abnormality
ELN Classiﬁcation
Genetic Risk Group
Number
of Induction
Cycles to
Obtain CR
WT1 BM
before ASCT
WT1 BM
after ASCT
Relapse
Post-ASCT
DFS (d) WT1 Levels
in LK Infused
1 71 M2 No Intermediate-I 1 55 23 No 2737 7
2 62 M1 FLT3 TKD Intermediate-I 1 8 8 No 2515 7
3 64 M4 No Intermediate-I 1 NA NA No 2404 36
4 69 M5 No Intermediate-I 1 NA NA No 2385 17
5 41 M2 No Intermediate-I 1 NA NA No 2377 8
6 61 M5 No Intermediate-I 1 25 19 No 2189 5
7 47 M5 No Intermediate-I 1 69 48 No 2006 61
8 76 M1 No Intermediate-I 1 NA 1156 Yes 1809 82
9 52 M1 No Intermediate-I 1 210 47 No 1805 4
10 57 M5 FLT3 ITD Intermediate-I 1 90 75 No 1784 11
11 24 M1 No Intermediate-I 1 55 100 No 930 10
12 28 M0 No Intermediate-I 1 115 91 No 929 20
13 60 M2 t(8:21) Favorable 1 44 10 No 876 15
14 68 M5 No Intermediate-I 1 32 14 No 747 17
15 72 M0 No Intermediate-I 2 7 12 Yes 626 75
16 68 undiff. No Intermediate-I 1 NA NA Yes 534 90
17 58 M5 CEBPAa mut Favorable 1 267 45 No 420 24
18 60 M0 No Intermediate-I 2 NA NA Yes 368 780
19 44 M5 No Intermediate-I 1 90 212 Yes 364 50
20 68 M4 No Intermediate-I 1 45 185 Yes 351 194
21 57 M1 No Intermediate-I 1 75 164 Yes 313 17
22 69 M2 No Intermediate-I 1 200 165 Yes 226 272
23 65 sAML No Intermediate-I 1 78 3 Yes 168 1
24 52 M2 inv(16) Favorable 1 12 0 Yes 141 23
25 72 M4 CEBPAa mut Favorable 1 86 506 Yes 116 61
26 75 sAML No Intermediate-I 1 324 82 Yes 93 840
27 77 M4 FLT3 ITD þ NPM1mut Intermediate-I 1 23 15 No 93 7
28 67 M4 No Intermediate-I 1 3 34 Yes 69 81
29 71 M0 No Intermediate-I 1 17 9 No 53 110
30 53 M4 Complex cariotype Adverse 1 1060 1619 Yes 52 421
FAB indicates, French-American-British; WT1, Wilms’ tumor gene 1; M0-5, AML subtypes according to FAB classiﬁcation; FLT3, fms-like tyrosine kinase 3; TKD,
FLT3 tyrosine kinase domain; NA, not available; ITD, internal tandem duplication; undiff, undifferentiated; CEBPAa, CCAAT/enhancer-binding protein alpha;
sAML, secondary AML.
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to death or to the last date of follow-up, whereas disease-free
survival (DFS) was calculated from the day of transplant to
the ﬁrst relapse date, progression or death, or to the last date
of follow-up. Survival rates were reported as 1-year
OS  standard error. Impact on survival of WT1-LK levels
was evaluated by comparing the survival curves by means of
the log-rank test. Adjustment for multiple group compari-
sons was performed according to Bonferroni method (sig-
niﬁcance level ¼ .05/number of tests). Comparison of the
therapeutic variables was performed retrospectively. The
independent prognostic value of variables was analyzed us-
ing the Cox proportional hazard model. Backward stepwise
regression was performed to identify the most powerful
predictors of survival. All probability values were 2-sided.
Analyses were carried out using the Statistica 4.0 statistical
package for Windows (Statsoft Inc, 1993, Tulsa, OK). Values
for P < .05 were considered statistically signiﬁcant.
RESULTS
We evaluated data from 30 patients with AML in CR1 who
received an ASCT between August 2005 and February 2013.
No patient died from transplant-related causes; after a me-
dian follow-up of 812 days (range, 52 to 2737) from ASCT, 14
patients (47%) relapsed and 16 were alive in CR. Median days
of DFS and OS were, respectively, 580 (range, 52 to 2737) and
812 (range, 53 to 2737). Four patients received an allogeneic
hematopoietic stem cell transplantation after relapse, 3 died
for toxicities related to the transplant, and 1 patient is alive in
second remission.Median WT1 transcript level in the PBSC graft of all 30
patients was 23 (range, 0 to 839). As a “negative” control
group, we evaluated the WT1 levels in the PBSCs collected
from 15 patients with different hematological diseases
without marrow involvement at time of LK and with noWT1
overexpression as molecular marker of active disease (14
multiplemyeloma, 2 Hodgkin lymphoma and 6 non-Hodgkin
lymphoma): median value was 16.6 (range, 1.5 to 71.8). The
difference between the 2 groups was not statistically sig-
niﬁcant (P ¼ .1), although the range was broader in AML
patients: we postulated that most of our AML patients had
“negative” values. Full data are reported in Table 2. The me-
dian WT1 transcript level in the PBSC graft of patients who
relapsed was signiﬁcantly higher than levels of those who
did not relapse after transplantation: 82 (range, 4 to 839) and
13 (range, 4 to 109) (P < .0001), respectively (Figure 1).
Cilloni et al. [8] previously published median WT1 levels
in PBSCs of mobilized healthy donors ranging from 0 to 39
(median, 6.1). In our control series the highest value of WT1
in LK of nonmyeloid tumoremobilized patients was 71.8 and
the value discriminating the 95th percentile was 68.9. We
deﬁned a cut-off level of 80 (ie, 1 decade above the 95th
percentile) to increase the speciﬁcity of our analysis. In fact,
using this value to deﬁne positive and negative PBSC grafts,
21 patients (group A) received negative and 9 patients (group
B) positive PBSCs, which strongly correlated with disease
recurrence (P ¼ .01, Fisher test). The deﬁned cut-off level had
a positive predictive value for relapse of 88.8% and negative
predictive value for relapse of 71.4%, with a sensitivity of
57.1% and a speciﬁcity of 93.7%.
Figure 2. Cumulative incidence of relapse of 30 patients receiving autologous
transplantation with apheresis containing  80 WT1 copies/ABL 10e4 (dotted
line, n ¼ 9) or <80 WT1 copies/ABL 10e4 (continuous line, n ¼ 21), P ¼ .0001.
Table 2
WT1 Quantitative Assessment in LK Control Samples
Type
of Sample
Number
of Samples
WT1 Copy Number/
104 ABL Copies
Median Range
Non-Hodgkin lymphoma LK 14 11.85 1.55-71.89
Hodgkin lymphoma LK 2 27.16 11.54-42.78
Multiple myeloma LK 6 30.46 1.55-51.82
Total LK 22 16.66 1.55-71.89
C. Messina et al. / Biol Blood Marrow Transplant 20 (2014) 1586e1591 1589The cumulative incidence of relapse (RI) was 30% in group
A and 87% in group B (P ¼ .0001). The observed 6- and 12-
month RI was, respectively, 14% and 24% for group A and
35% and 61% for group B (Figure 2).
One-year DFS and OS rates were, respectively, 75% (95%
conﬁdence interval [CI], 58% to 97%) and 90% (95% CI, 77% to
100%) for group A and 25% (95% CI 8% to 84%) and 25% (95% CI
8% to 84%) for group B. Median DFS was not reached for
group A, whereas it was 351 days for group B (P ¼ .0001)
(Figure 3). Median OS was signiﬁcantly better for group A
than for group B: not reached and 351 days, respectively
(P ¼ .001) (Figure 4).
WT1 transcript levels were evaluated in the BM of 25 and
24 patients before PBSC collection by LK and before ASCT,
respectively. Median WT1 transcript levels in the BM before
LK and ASCT were 56 (range, 6 to 1048) and 62 (range, 3 to
1060), respectively. Five patients had BM WT1 levels > 250
before LK (copies: 283, 583, 646, 950, and 1048); 2 of these
patients were LK negative and 1 did not relapse. Three pa-
tients had BM WT1 levels > 250 before ASCT (copies: 267,
324, and 1060); 1 of these patients received a PBSC product
that was LK negative and is still in remission.
Table 1 also shows WT1 levels in BM after ASCT in 25
evaluated patients. In 5 patientsWT1 levels in the PBSC graft
and in the ﬁrst BM evaluated after ASCT (mostly around
day þ30) did not correlate: in 4 patients who were BM
negative WT1-LK was positive and 3 of them relapsed, and
only 1 patient who was WT1-LK negative became BM posi-
tive and relapsed. These data suggest a possible stronger
correlation with outcome of WT1-LK than day þ30 BM-WT1
levels, but numbers are still too small to draw any conclusion.
As previously reported by the European Group for Blood
and Marrow Transplantation (EBMT) survey [13], the dose of
CD34þ cells infused could inﬂuence the relapse rate afterFigure 1. Median LK-WT1 copy number (copies/ABL 10e4) of AML relapsed
patients (right column, n ¼ 14) and in those in continuous CR (left column,
n ¼ 16): 82 (range, 4 to 839) versus 13 (range, 4 to 109), respectively (P < .001).ASCT. In particular, infusion of >7.16  106/kg CD34þ cells
correlated with increased relapse incidence and lower
leukemia-free survival (LFS). We analyzed the correlation of
the dose of CD34þ cells infused in our patients with outcome
andWT1-LK levels. In our series, 6 patients received a CD34þ
cell dose 7  106/kg and 5 patients relapsed. All received a
WT1-LK product positive, and the patient who did not
relapse received a WT1-LK product negative.
DISCUSSION
Postremission ASCT can extend survival in a selected
subgroup of AML patients [14]. Several studies reported that
ASCT using mobilized PBSCs offers a faster hematopoietic
recovery and is associated with limited morbidity and
treatment-related mortality than after BM harvest infusion
[15-17]. However, a retrospective cohort analysis from the
EBMT of 2165 AML patients in CR1 reported a higher inci-
dence of relapse after ASCT with PBSCs than with BM stem
cells [18]. The authors postulated that recruitment of
leukemic cells during mobilization of PBSC with granulocyteFigure 3. DFS of 30 patients receiving autologous transplantation with
apheresis containing 80 WT1 copies/ABL 10e4 (dotted line, n ¼ 9) or <80
WT1 copies/ABL 10e4 (continuous line, n ¼ 21), P ¼ .0002.
Figure 4. OS of 30 patients receiving autologous transplantation with apher-
esis containing 80 WT1 copies/ABL 10e4 (dotted line, n ¼ 9) or <80 WT1
copies/ABL 10e4 (continuous line, n ¼ 21), P  .0001.
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tion may have accounted for the higher incidence of relapse
after transplantation. This hypothesis ﬁnds support from the
following observations: (1) a direct correlation between RI,
LFS, and CD34þ PBSCs infused reported by a retrospective
EBMT study [13] and (2) a 32% reduction in RI and 29% in-
crease in 4-year LFS by “in vitro” purging with mafosfamide
and a 25% increase in 3-year LFS by “in vitro” purging with 4-
hydroperoxycyclophosphamide, respectively, reported by
the EBMT [19,20] and by the Center for International Blood
and Marrow Transplant Research [21,22].
In this context and in the perspective of optimization of
ASCT clinical indication, a quantitative assessment of a reli-
able marker of MRD in LK of autologous PBSCs could be a
useful tool in determining the relapse risk after ASCT.WT1 is
a tumor-suppressor gene coding for a zinc-ﬁnger transcrip-
tion factor located on chromosome 11p13, involved in the
pathogenesis of theWilms’ tumor [23]. In normal PB and BM,
WT1 expression is low and often undetectable even by
qualitative reverse transcriptase PCR [24], whereas it is
overexpressed in nearly 90% of AML cases [25-27]. Our data
show that real-time quantiﬁcation ofWT1 transcripts in PBSC
collections of patients with multiple myeloma, non-Hodgkin
lymphoma, and Hodgkin lymphoma were low (16.6; range,
1.5 to 71.8). Based on these results and considering that, once
prospectively validated, WT1 levels on LK could be poten-
tially used to tailor treatment of most patients with positive
LK toward more aggressive approaches, we choose to value
speciﬁcity over sensitivity of the exam. Thus, we deﬁned 80,
which was 1 decade above the value of the 95th percentile of
our controls, as the cut-off value.
In our study, all patients with WT1-LK levels above 80
relapsed, and the difference in relapse incidence and DFSwas
signiﬁcant when compared with patients with WT1-LK
levels lower than 80. Of note, 4 of 9 patients with higher
WT1-LK levels and who relapsed had normal BMWT1 levels
at the time of LK. This may suggest that WT1 in BM is less
predictive than WT1 in LK after mobilization. This difference
could be explained by the recruitment of leukemic cells from
all body sites under granulocyte colony-stimulating factor
stimulation and supports WT1 in LK as a useful marker ofwhat is really infused. Our results are also in accordance with
those from a study that quantiﬁed MRD in BM harvests used
for autografting in AML. According to those data, higherWT1
levels detected by PCR were associated with aworse relapse-
free survival [6].
In a similar attempt to establish individual prognostic
tools, Milone et al. [28] analyzed 96 AML patients in CR1 for
peak CD34þ cell levels in PB during PBSC mobilization and
harvest, irrespective of postremission treatment received.
The peak of CD34þ cells in PB was an independent predictor
for DFS in multivariate analysis. Studies in AML using ﬂow
cytometry have demonstrated that the levels of cells
expressing an aberrant phenotype in BM harvests correlated
with disease recurrence [29].
Regarding the relationship between the number of
CD34þ/kg infused and WT1 levels in LK and RI post-ASCT in
our series, only 1 in 5 patients who received a megadose of
CD34 did not relapse. This patient was the only who received
WT1 negative LK. If conﬁrmed in larger trials, these data
would support the role of MRD evaluation in PBSC product
irrespective to CD34 dose infused.
Our study represents the largest series of patients eval-
uating WT1 as a marker of MRD in PBSC LK products. How-
ever, we would like to remark on 2 points of our study. First,
the number of patients is still insufﬁcient to provide a strong
recommendation about postconsolidation strategy. The low
number of patients in our study is due to both the competing
option of allogeneic transplantation, which at the 2 centers is
offered to patients up to age 70 years, and the rate of suc-
cessful autologous LK, which was around 50% to 60%. Second,
we could not explain with certainty if patients with low
WT1-LK did better because of less tumor contamination of
the LK products or because they were the better responders
to chemotherapy. We observed only 3 patients withWT1 BM
positive before ASCT and 2 of them, both with WT1-LK
product positive, relapsed after ASCT. Only 4 patients had
WT1 BM negative before ASCT and WT1-LK products posi-
tive, and 3 of them relapsed. Patients received similar
treatments, according to internal policies at the 2 centers.
Although we cannot formally exclude that the outcome of
patients was inﬂuenced by the differences among the che-
motherapic regimens, in our opinion this point was not
relevant for the purposes of our study because all regimens
administered can be considered equivalent options for AML
treatment.
In summary, our results validate the use of RQ-PCR ofWT1
transcripts for MRD quantiﬁcation in PBSC products of AML
patients and suggest that higher MRD levels reﬂect a higher
grade of contamination by leukemic cells. We conclude that a
completely standardized real-time WT1-reverse transcrip-
tase-PCRebased assay could address patients with negative
PBSC LK products to ASCT with a projected long-term sur-
vival without AML relapse, whereas patients with contami-
nated PBSCs (80 WT1-LK copies) could better beneﬁt of
further in vivo purging with chemotherapy before a second
PBSC collection. Alternatively, in a context in which an
alternative donor (eg, matched unrelated donor, hap-
loidentical donor, cord blood) is available for most patients
and reduced-intensity conditioning can be offered also to
healthy patients older than 65 years, we suggest that these
patients should be considered for allogeneic stem cell
transplantation. We believe our results represent the basis
for a prospective study incorporating operationally a WT1
MRD analysis of the PBSC graft as an individual patient’s
adapted postremission allocation strategy.
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